行情

EXEL

EXEL

伊克力西斯
NASDAQ

实时行情|Nasdaq Last Sale

16.65
+0.19
+1.15%
已收盘, 17:35 04/02 EDT
开盘
16.28
昨收
16.46
最高
16.73
最低
15.95
成交量
251.10万
成交额
--
52周最高
25.20
52周最低
13.67
市值
50.85亿
市盈率(TTM)
16.34
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测EXEL价格均价为24.46,最高价位35.00,最低价为19.00。

EPS

EXEL 新闻

更多
  • 3 Top Stocks That Will Make You Richer in Q2 (and Beyond)
  • MotleyFool.com · 22小时前
  • XBI: Biotech ETF Expected To Outperform During And After The Coronavirus Pandemic
  • Seeking Alpha - Article · 2天前
  • 3 Covid-19 Proof Biotech Stocks
  • Seeking Alpha - Article · 3天前
  • Were These Hedge Funds Right About Selling Exelixis, Inc. (EXEL)?
  • Insider Monkey · 03/26 19:41

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.80%

热门股票

代码
价格
涨跌幅

EXEL 简况

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
展开

微牛提供Exelixis, Inc.(NASDAQ-EXEL)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的EXEL股票新闻,以帮助您做出投资决策。